Hepatobiliary & Pancreatic Diseases International

Hepatobiliary & Pancreatic Diseases International

Copyright 2017, Hepatobiliary & Pancreatic Diseases International. All rights reserved. www.hbpdint.com

General information

Hepatobiliary & Pancreatic Diseases Internationalis a journal published bimonthly in the English language by the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. We welcome original research articles, review articles, editorials, and others from any part of the world. Manuscripts are reviewed by members of the international editorial board and our expert peer reviewers, then either accepted for publication or rejected by the chief editor.Manuscripts should be submitted viahttps:// mc03.manuscriptcentral.com/hbpdint.

Most of submissions accepted for publication may undergo revisions recommended by the reviewers, editors or statistical advisers. A decision takes from two weeks to three months, the longer period being due to the multiple reviews needed for articles likely to be accepted. Publication varies from two to six months after final acceptance. Proofs of edited articles and illustrations are sent to the corresponding author for correction and reply to any queries from editors. A sample copy of the journal containing the articles will be forwarded to the corresponding author within a few days of publication.

Online submissions

Original research articlesincluding randomized trials, intervention studies, studies of screening and diagnostic tests, cohort studies, cost-effectiveness analyses and case control studies should be prepared in accordance with theUniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org). Those of randomized controlled trials (RCTs) should follow the CONSORT-statement (www.consort-statement.org). The reporting of other articles should follow the guidelines set by the different initiatives or groups listed in the appendix. The article should be submitted with two separate files, one with detailed information about authors and the title, short running title, source of the work, in addition to the names, address, telephone and fax number or email address for the corresponding author. Another file should show only the title, running title, abstract, main text, tables, figures of the submitted article as well as a list of references, which will be sent to reviewers.

The authors’ names (normally no more than six) and their initials should be in the same form as in their other publications with one major qualification such as MD or PhD, their current appointment and a full postal address. One author should be named for editorial correspondence.

Each submission must be accompanied by a letter of copyright transfer signed by all the authors (see the detailed description in the last section) and other relevant documents including informed consent obtained from research subjects and research approval from the supervising or institutional ethics bodies. Author(s) of each submission should clarify the functions in or contributions to their research and declare, if any, competing interest. A choice of one of the following statements will be requested when a decision has been made to accept the paper:

1. The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article.

3. The author or authors do not choose to declare any conflict of interest related directly or indirectly to the subject of this article.

The statements selected by the author or authors will be published with the article. The signature of each author will be required. No article will be published until the completed form has been received at theHepatobiliary & Pancreatic Diseases Internationaloffice.

Manuscripts should be prepared with generous margins, and double spacing is essential throughout the text, the references and the captions. Tables, figures, captions and list of references should appear properly in the text. The style should be simple and direct, free from ambiguity and jargon, and with minimal use of abbreviations.

Thetitleof the paper should be chosen with care: a short one has more impact and may be expanded by a subtitle.

Structured abstractof original articles should includefour sections as Background, Methods, Results and Conclusions and have no more than 300 words summarizing the most important points in the article, incorporating key words suitable for electronic retrieval systems.Background:This section should provide a precise statement of the primary focus of the study and the context in which it was carried out.Methods:This section describes how the study was performed, including details of clinical and/or technical procedures.Results:This section describes the salient results of the study.Conclusions:This section covers conclusions and their clinical application or others, while equal emphasis should be given to positive and negative findings of equal scienti fic merit.

Themain textshould be divided under headings. For many research papers the best sequence is Introduction, Methods (Materials or Patients), Results, and Discussion. The text should comment on, but should not repeat, the details given in tables, figures or captions. Any acknowledgements should be made at the end of the main text.

Introduction:This should explain the problem which is to be addressed, with a de finition of the hypothesis to be examined if appropriate, out-lining, brie fly, its relevance to the appropriate literature.

Methods (Materials or Patients):The subjects of the study and the methods employed in the investigation must be clearly described. For example, the reasons for examining the particular group of patients should be made clear, and reasons for exclusion of individuals from the study must be stated. Any group used as controls must be defined accurately.

Ethical approval of studies and informed consent are required. For all manuscripts reporting data from studies involving human participants or animals, formal review and approval, or formal review and waiver, by an appropriate institutional review board or ethics committee is required and should be described in the Methods section. For those investigators who do not have formal ethics review committees, the principles outlined in theDeclaration of Helsinkishould be followed. For investigations of humans, state in the Methods section the manner in which informed consent was obtained from the study participants (i.e., oral or written). Editors may request that authors provide documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study.

Results:These must be clearly expressed in simple language. Tables or similar diagrams can be used but must not duplicate material already described in the text.

Discussion:This section must be succinct, pointing out the relevance of the work described in the article and its contribution to current knowledge. The results must be interpreted clearly, and both strength and weakness expressed. Discussion of pertinent references must be concise and short.

Each of thetablesshould have a short descriptive heading.

Thereferencesin the text should include only those that are important and have been studied fully by the authors. The authors are responsible for the accuracy and completeness of the cited references and for correct citation of the text. When listing references the names of journals should be abbreviated according to Index Medicus (List all authors and/or editors up to 6; if more than 6, list the first 6 and et al). All references will be checked deliberately by the authors; PMID roots in the abstract serial number indexed by PubMed (http://www.ncbi.nlm.nih. gov/sites/entrez?db=PubMed) are requested. The references cited should be represented in the text by superscript numbers in the order of their appearance. The list of references at the end of the text should be in this numerical order with details and punctuation as follows:

Article from journal—more than one author

Yan S, Zhang QY, Yu YS, He JJ, Wang WL, Zhang M, et al. Microsurgical reconstruction of hepatic artery in living donor liver transplantation: experiences and lessons. Hepatobiliary Pancreat Dis Int 2009;8:575-580. PMID: 20007072

Article from journals with English abstracts only

Ma Y, Hu AB, Xiong J. Migration of donor dendritic cell inducing graft acceptance in combined transplantation of liver and kidney [abstract in English]. Zhonghua Shi Yan Wai Ke Za Zhi 2006;23:750-752.

Monographic series

Davidoff RA. Migraine: manifestations, pathogenesis, and management. Philadelphia, Pa: FA Davis; 1995. Contemporary Neurology Series, No. 42.

Online journals with volume and page information

Simon JA, Hudes ES. Relationship of ascorbic acid to blood lead levels. JAMA 1999;281:2289-2293. PMID: 10386552. Accessed June 11, 2009. http://jama.ama-assn. org/cgi/content/full/281/24/2289

Online journals without volume and page information

Verschuur EM, Steyerberg EW, Tilanus HW, PolinderS, Essink-Bot ML, Tran KT, et al. Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. Br J Cancer 2008 Dec 9. PMID: 19066612 doi: 10.1038/sj.bjc.6604811

Online website

Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis [serial online] 1995 Jan-Mar [cited 1996 Jun 5]; 1(1): [24 screens]. Available from: www.cdc. gov/ncidod/eid/vol1no1/morse.htm

Book—more than one author (list all authors if six or less, otherwise list first three followed by et al)

Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man, 4th ed. Foster City, CA: Chemical Toxicology Institute;1995.

Chapter from a book

Calne RY. Experimental background. In: Calne RY, ed. Liver transplantation, 2nd ed. London: Grune & stratton; 1987:3-7.

Book—with editors

Maddrey WC, ed. Transplantation of the liver. New York: Elsevier Science Publishing;1998.

IllustrationsPhotographs, drawings, diagrams, charts and graphs should meet the editorial demands. The “threedimensional” bar charts produced by computer programs are not acceptable. Photomicrographs with no inset scale should have the magni fication of the print in the caption; stains should be indicated. The lettering on diagrams and graphs should be large enough to be clear after it has been reduced for printing and be consistent in size and style. Color will be accepted only where it is essential. Permission to reproduce any borrowed illustration must be obtained from the author and the publisher, and evidence of this permission must accompany the submitted article.

Review articlesare welcome especially systematic, critical assessments of the literature and data sources pertaining to clinical topics, emphasizing factors such as cause, diagnosis, prognosis, therapy, or prevention. All articles and data sources reviewed should include information about the speci fic type of study or analysis, population, intervention, exposure, and tests or outcomes. All articles or data sources should be selected systematically for inclusion in the review and critically evaluated, and the selection process should be described in the article. Meta-analyses also will be considered as review articles. Editors ask potential authors of review articles to check the MOOSE initiative for meta-analysis of observational studies in epidemiology (See the appendix).

Letters to the editoron matters of recently published articles in the journal are especially welcome, which should not exceed 400 words. Letters of general interest, unlinked to items published in the journal, can be up to 1500 words long and are to be sent for peer-reviewed. Correspondence letters are not usually peer reviewed, but the journal might invite replies from the authors of the original publication, or pass on letters to these authors. Only two tables or figures are permitted, and there should be no more than 10 references and six authors. All accepted letters are edited, and proofs will be sent out to authors before publication.

Appendix. Reporting guidelines for study designs

Notes, news or announcementsfor conferences, symposia or meetings may be sent for publication at least 3 months before the required date of publication. These are mostly included under Meetings and Courses without payment. Provide title, date(s) and place of the event and contact address, telephone, and email address.Hepatobiliary & Pancreatic Diseases Internationalreserves the right to be selective in publishing these announcements. Those wishing for a detailed publication may submit as advertisements. For academic information, subsidized rates are available.

Letter of copyright transfer

We require a letter of copyright transfer signed by all named authors, stating that they have taken a significant and active part in the preparation of the article, that they have read and approved the final version, and are willing to discuss it in detail. This is essential for the reviewing process to be completed. Possibly duplicative materials (i.e., those containing substantially similar content or using the same or similar data) that have been previously published or are being considered elsewhere must be provided at the time of manuscript submission.

To conform with theCopyright Act of China, this letter must contain the following paragraph:

In consideration ofHepatobiliary & Pancreatic Diseases Internationalreviewing and editing my (our) submission, the author(s) undersigned hereby transfer(s), assign(s), or otherwise conveys all copyright ownership toHepatobiliary & Pancreatic Diseases Internationalrepresent(s) that he (they) own(s) all rights in the material submitted. The author(s) further confirm(s) that the article is original, that it is not under consideration by another journal in any language, and that it has not been previously published, in whole or in part, in another journal in any language. There is no conflict of interests relevant to the study reported in this article.

For convenience potential author can download the form of the letter from our journal’s website. This assignment is to take effect only if the work is accepted for publication inHepatobiliary & Pancreatic Diseases International.

These instructions can also be found on the journal’s website atwww.hbpdint.comand may be copied by those intending to submit an article.

Letter of Copyright Transfer___________________

Your name (printed)__________________________

Tel__________________Fax___________________

Email______________________________________

Manuscript entitled:__________________________

We have taken a significant and active part in the preparation of the article, and we have read and approved the final version. We are willing to discuss it in detail.

In consideration ofHepatobiliary & Pancreatic Diseases Internationalreviewing and editing my(our) submission, the author(s) undersigned hereby transfer(s), assign(s), or otherwise conveys all copyright ownership toHepatobiliary & Pancreatic Diseases Internationalrepresent(s) that he(they) own(s) all rights in the material submitted. The author(s) further confirm(s) that the article is original, that it is not under consideration by another journal in any language, and that it has not been previously published, in whole or in part, in another journal in any language. There is no conflict of interests relevant to the study reported in this article.

This assignment is to take effect only if the work is accepted for publication inHepatobiliary & Pancreatic Diseases International.

Authors’ name(s) in order of appearance in the manuscript, signatures (date):

1. Full name (printed):_________________________

Abbreviated name in PubMed (printed):____________

Signed (handwritten):__________________________

Date:_______________________________________

2. Full name (printed):__________________________

Abbreviated name in PubMed (printed):_____________

Signed (handwritten):___________________________

Date:________________________________________

3. Full name (printed):___________________________

Abbreviated name in PubMed (printed):_____________

Signed (handwritten):___________________________

Date:________________________________________

efits in any form have been

or will be received from a commercial party related directly or indirectly to the subject of this article.

_________________________

Email______________________________________

10.1016/S1499-3872(17)60028-6)